Total Payments
$6,651
2024 Payments
$283.15
Companies
36
Transactions
146
Medicare Patients
2,081
Medicare Billing
$320,114
Payment Breakdown by Category
Food & Beverage$5,614 (84.4%)
Travel$611.74 (9.2%)
Education$424.99 (6.4%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,614 | 136 | 84.4% |
| Travel and Lodging | $611.74 | 2 | 9.2% |
| Education | $424.99 | 8 | 6.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Foundation Medicine, Inc. | $4,109 | 6 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $366.42 | 23 | $0 (2024) |
| Amgen Inc. | $249.61 | 16 | $0 (2023) |
| Alexion Pharmaceuticals, Inc. | $221.39 | 3 | $0 (2019) |
| Genentech USA, Inc. | $189.03 | 14 | $0 (2022) |
| Janssen Biotech, Inc. | $179.02 | 7 | $0 (2024) |
| PFIZER INC. | $161.14 | 10 | $0 (2023) |
| Celgene Corporation | $134.10 | 6 | $0 (2024) |
| ABBVIE INC. | $90.99 | 4 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $90.33 | 6 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $283.15 | 13 | ABBVIE INC. ($55.19) |
| 2023 | $252.61 | 13 | Celgene Corporation ($81.80) |
| 2022 | $167.37 | 8 | PFIZER INC. ($31.80) |
| 2021 | $27.49 | 2 | Novartis Pharmaceuticals Corporation ($15.57) |
| 2020 | $255.05 | 10 | Janssen Biotech, Inc. ($99.95) |
| 2019 | $752.93 | 37 | Alexion Pharmaceuticals, Inc. ($198.00) |
| 2018 | $4,471 | 34 | Foundation Medicine, Inc. ($4,047) |
| 2017 | $440.83 | 29 | Novartis Pharmaceuticals Corporation ($81.94) |
All Payment Transactions
146 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/12/2024 | SERVIER PHARMACEUTICALS LLC | Voranigo (Drug) | Food and Beverage | In-kind items and services | $21.77 | General |
| Category: Oncology | ||||||
| 11/07/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $18.50 | General |
| Category: Oncology | ||||||
| 09/20/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $14.13 | General |
| Category: Oncology | ||||||
| 08/22/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Food and Beverage | In-kind items and services | $27.16 | General |
| Category: ONCOLOGY | ||||||
| 08/19/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $30.76 | General |
| Category: ONCOLOGY | ||||||
| 06/15/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $14.75 | General |
| Category: ONCOLOGY | ||||||
| 06/12/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $17.08 | General |
| Category: Oncology | ||||||
| 05/15/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $24.43 | General |
| Category: ONCOLOGY | ||||||
| 05/06/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $26.74 | General |
| Category: Hematology | ||||||
| 05/03/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $18.45 | General |
| Category: Oncology | ||||||
| 04/29/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Food and Beverage | In-kind items and services | $27.72 | General |
| Category: ONCOLOGY | ||||||
| 04/26/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $25.56 | General |
| 01/09/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $16.10 | General |
| Category: Oncology | ||||||
| 12/01/2023 | Amgen Inc. | — | Education | In-kind items and services | $12.84 | General |
| 11/10/2023 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $24.75 | General |
| Category: Hematology | ||||||
| 10/30/2023 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $14.97 | General |
| Category: Hematology | ||||||
| 10/26/2023 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $28.84 | General |
| Category: Hematology | ||||||
| 10/19/2023 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $13.24 | General |
| Category: Hematology | ||||||
| 09/06/2023 | Amgen Inc. | — | Education | In-kind items and services | $15.49 | General |
| 07/27/2023 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $23.84 | General |
| Category: Oncology | ||||||
| 06/14/2023 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $15.34 | General |
| Category: Oncology | ||||||
| 05/13/2023 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $19.37 | General |
| Category: ONCOLOGY | ||||||
| 05/08/2023 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: Oncology | ||||||
| 02/21/2023 | PFIZER INC. | INLYTA (Drug), BAVENCIO, LORBRENA | Food and Beverage | In-kind items and services | $16.66 | General |
| Category: ONCOLOGY | ||||||
| 01/20/2023 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI | Food and Beverage | In-kind items and services | $24.69 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 433 | 727 | $100,255 | $55,713 |
| 2022 | 5 | 521 | 858 | $162,514 | $76,841 |
| 2021 | 6 | 517 | 981 | $154,891 | $89,693 |
| 2020 | 7 | 610 | 1,217 | $194,053 | $97,866 |
Total Patients
2,081
Total Services
3,783
Medicare Billing
$320,114
Procedure Codes
35
All Medicare Procedures & Services
35 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 230 | 499 | $61,227 | $34,707 | 56.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 45 | 47 | $12,384 | $6,359 | 51.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 44 | 44 | $9,239 | $5,159 | 55.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 20 | 38 | $5,706 | $3,553 | 62.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 61 | 65 | $5,172 | $2,770 | 53.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 12 | 12 | $4,311 | $1,929 | 44.7% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Facility | 2023 | 21 | 22 | $2,216 | $1,236 | 55.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 187 | 409 | $76,533 | $36,619 | 47.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 144 | 232 | $36,353 | $16,509 | 45.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 60 | 60 | $21,480 | $9,650 | 44.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 29 | 30 | $8,220 | $4,516 | 54.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 22 | 22 | $6,435 | $3,185 | 49.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 16 | 33 | $4,653 | $2,646 | 56.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 31 | 33 | $4,257 | $2,047 | 48.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 32 | 39 | $4,583 | $1,668 | 36.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 204 | 546 | $79,716 | $49,476 | 62.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 64 | 64 | $17,856 | $10,686 | 59.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 57 | 142 | $20,732 | $10,044 | 48.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 41 | 42 | $11,462 | $6,545 | 57.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 73 | 79 | $7,979 | $5,031 | 63.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 39 | 59 | $5,959 | $2,755 | 46.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 14 | 23 | $3,229 | $1,754 | 54.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 13 | 13 | $3,627 | $1,745 | 48.1% |
| 38222 | Diagnostic aspirations and biopsies of bone marrow | Office | 2021 | 12 | 13 | $4,331 | $1,657 | 38.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 247 | 705 | $102,930 | $55,246 | 53.7% |
About Dr. Muhammad Hamdan, MD
Dr. Muhammad Hamdan, MD is a Hematology & Oncology healthcare provider based in Lansing, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1528091980.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Muhammad Hamdan, MD has received a total of $6,651 in payments from pharmaceutical and medical device companies, with $283.15 received in 2024. These payments were reported across 146 transactions from 36 companies. The most common payment nature is "Food and Beverage" ($5,614).
As a Medicare-enrolled provider, Hamdan has provided services to 2,081 Medicare beneficiaries, totaling 3,783 services with total Medicare billing of $320,114. Data is available for 4 years (2020–2023), covering 35 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Lansing, MI
- Active Since 07/09/2006
- Last Updated 05/01/2014
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1528091980
Products in Payments
- FOUNDATIONACT (Device) $4,047
- SOLIRIS (Drug) $221.39
- ERLEADA (Drug) $99.95
- Kyprolis (Biological) $93.78
- VOTRIENT (Drug) $85.34
- OPDIVO (Biological) $75.99
- KISQALI (Drug) $74.24
- Pomalyst (Drug) $66.83
- Nplate (Biological) $66.05
- FOUNDATIONONE (Device) $62.31
- IMBRUVICA (Drug) $57.95
- XTANDI (Drug) $57.51
- EPKINLY (Drug) $55.19
- ZALTRAP (Drug) $54.99
- Vanflyta (Drug) $54.88
- ALIMTA (Drug) $45.55
- LIBTAYO (Biological) $42.74
- BRAFTOVI (Drug) $41.84
- REBLOZYL (Biological) $41.71
- KEYTRUDA (Biological) $41.10
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Lansing
Dr. Gordon Srkalovic, Md, MD
Hematology & Oncology — Payments: $348,363
Hematology & Oncology $348,363
Dr. Jatin Rana, M.d, M.D
Hematology & Oncology — Payments: $2,250
Hematology & Oncology $2,250
Dr. Cheryl Kovalski, D.o, D.O
Hematology & Oncology — Payments: $850.41
Hematology & Oncology $850.41
Dr. Saud Alsubait
Hematology & Oncology — Payments: $186.21
Hematology & Oncology $186.21
Diane Macdonald, M.d, M.D
Hematology & Oncology — Payments: $134.17
Hematology & Oncology $134.17
Dr. Kenneth Schwartz, M.d, M.D
Hematology & Oncology
Hematology & Oncology